# Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

Study · id `cardio:ct-nct06187727` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06187727](<https://clinicaltrials.gov/study/NCT06187727>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06187727

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

## Technical summary

Registry record NCT06187727. Randomized; double masking; primary purpose treatment. Start 2023-07-01 (actual); primary completion 2025-01-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 248 participants (enrolled count; ClinicalTrials.gov record NCT06187727, source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)
- Started: 2023-07-01 (actual) (ClinicalTrials.gov record NCT06187727, source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)
- Primary completion: 2025-01-01 (actual) (ClinicalTrials.gov record NCT06187727, source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)
- Completion: 2025-10-01 (actual) (ClinicalTrials.gov record NCT06187727, source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06187727, source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06187727-2025-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
- Acronym: Health
- Condition: Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): Henagliflozin
- Lead sponsor: Qian geng
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: d8d6f223a79d0ac51f46fd7f87b859d7e888a81a9b393ba97b86c10ab0757af8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
